$33.05
0.54% day before yesterday
Nasdaq, Dec 24, 08:52 pm CET
ISIN
US00773J1034
Symbol
SYRE

Aeglea BioTherapeutics Inc Stock price

$33.05
+6.08 22.54% 1M
+17.64 114.47% 6M
+9.77 41.97% YTD
+9.71 41.60% 1Y
+24.07 267.94% 3Y
-170.20 83.74% 5Y
-211.20 86.47% 10Y
-211.20 86.47% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
-0.18 0.54%
ISIN
US00773J1034
Symbol
SYRE
Industry

Key metrics

Basic
Market capitalization
$2.6b
Enterprise Value
$2.1b
Net debt
positive
Cash
$486.2m
Shares outstanding
60.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
5.6
Financial Health
Equity Ratio
85.2%
Return on Equity
-40.2%
ROCE
-48.8%
ROIC
6,999.1%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
- | $-217.1m
EBIT
$-224.0m | $-213.8m
Net Income
$-149.0m | $-131.0m
Free Cash Flow
$-162.0m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -3.9%
EBIT
-15.1% | -2.3%
Net Income
30.7% | 37.0%
Free Cash Flow
-7.3%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-2.5
FCF per Share
$-2.7
Short interest
17.4%
Employees
65
Rev per Employee
$0.0
Show more

Is Aeglea BioTherapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Aeglea BioTherapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a Aeglea BioTherapeutics Inc forecast:

18x Buy
95%
1x Hold
5%

Analyst Opinions

19 Analysts have issued a Aeglea BioTherapeutics Inc forecast:

Buy
95%
Hold
5%

Financial data from Aeglea BioTherapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 47 47
5% 5%
-
- Research and Development Expense - -
-
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -224 -224
15% 15%
-
Net Profit -149 -149
31% 31%
-

In millions USD.

Don't miss a Thing! We will send you all news about Aeglea BioTherapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aeglea BioTherapeutics Inc Stock News

Neutral
GlobeNewsWire
20 days ago
WALTHAM, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease and rheumatic diseases, today announced that Spyre's independent Compensation Committee of the Board of Directors ap...
Neutral
GlobeNewsWire
about 2 months ago
WALTHAM, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases, today announced that Spyre's independent Compensation Committee of the Board of Dire...
Neutral
GlobeNewsWire
about 2 months ago
Reported positive interim Phase 1 results for SPY003, a next-generation anti-IL-23 antibody, demonstrating the molecule was well-tolerated and exhibited an ~85-day half-life supporting quarterly or twice annual maintenance dosing
More Aeglea BioTherapeutics Inc News

Company Profile

Aeglea Biotherapeutics, Inc. operates as a clinical-stage biotechnology company, which develops next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.

Head office United States
CEO Cameron Turtle
Employees 65
Founded 2013
Website spyre.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today